Last week the Canadian Pest Management Association submitted the following comments to Health Canada’s Pest Management Regulatory Agency with regards to PRVD2017-03: Proposed Registration Decision, Lambda-Cyhalothrin, published June 23, 2017. The proposed decision would cancel all all indoor residential use patterns of lambda-cyhalothrin by commercial applicators. CPMA believes that PMRA did not adequately consider the tremendous value of lambda-cyhalothrin and it’s important role as primary tool in integrated pest management. CPMA also believes that PMRA relied on inaccurate data and skewed assumptions of exposure with regards to the structural pest management industry; and lastly CPMA is disappointed that as an industry we were not involved in this reevaluation decision sooner to provide further input on how minimally this product is used in indoor residential settings.
On September 27th the CPMA Board of Directors met with PMRA to specifically discuss the proposed decision and presented the case to retain lambda-cyhalothrin in Canada. PMRA and CPMA agreed to continue a dialogue throughout the final decision and potentially discuss further label mitigation at a later date.
In addition to speaking about lambda cyhalothrin with PMRA, the CPMA Board of Directors also spoke about setting national pesticide applicator certification and training standards, which would require each Province to set some form of continuing education and testing standards. PMRA agreed to speak further on what the regulatory framework would entail in the near future.
Click here to view submitted comments.